dc.creator | Mantzana, P. | en |
dc.creator | Pournaras, S. | en |
dc.creator | Skentou, C. | en |
dc.creator | Deligeoroglou, E. | en |
dc.creator | Katsioulis, A. | en |
dc.creator | Antonakopoulos, G. | en |
dc.creator | Hadjichristodoulou, C. | en |
dc.creator | Tsakris, A. | en |
dc.creator | Messinis, I. E. | en |
dc.creator | Daponte, A. | en |
dc.date.accessioned | 2015-11-23T10:38:49Z | |
dc.date.available | 2015-11-23T10:38:49Z | |
dc.date.issued | 2014 | |
dc.identifier | 10.2217/fvl.14.11 | |
dc.identifier.issn | 1746-0794 | |
dc.identifier.uri | http://hdl.handle.net/11615/30678 | |
dc.description.abstract | Aim:To conduct a pilot cross-sectional study to evaluate the rates of detection of four common high-risk HPV (hr-HPV) types using first-void urine paired with vaginal self-obtained samples in a nonvaccinated population of pregnant women. We also aimed to compare these results with a matched nonpregnant group in order to test the applicability of self-sampled hr-HPV cervical cancer screening during antenatal visits. Materials & methods: Samples from 550 pregnant women were subjected to hr-HPV-16, -18, -31 and -45 type detection by inhouse PCR and compared with 250 paired urine, vaginal and cervical samples from an age-matched cohort of nonpregnant women. Results: Comparing overall hr-HPV prevalence in urine and vaginal samples between pregnant (15 out of 550; 2.7%) and nonpregnant women (eight out of 250; 3.2%) for each HPV type revealed no significant differences. All paired urine/vaginal samples were both positive for the same type of hr-HPV and there was no positive urine sample with the other samples being negative. Conclusion: hr-HPV detection in pregnant women using self-obtained urine and vaginal samples seems to be a feasible cervical cancer screening method. | en |
dc.source | Future Virology | en |
dc.source.uri | <Go to ISI>://WOS:000335564900010 | |
dc.subject | HPV-16 | en |
dc.subject | HPV-18 | en |
dc.subject | HPV-31 | en |
dc.subject | HPV-45 | en |
dc.subject | HPV pregnancy | en |
dc.subject | HPV urine | en |
dc.subject | HPV vagina | en |
dc.subject | screening | en |
dc.subject | self-sampling | en |
dc.subject | HUMAN-PAPILLOMAVIRUS DNA | en |
dc.subject | RISK HUMAN-PAPILLOMAVIRUS | en |
dc.subject | OF-THE-LITERATURE | en |
dc.subject | REAL-TIME PCR | en |
dc.subject | COLLECTED SAMPLES | en |
dc.subject | CHLAMYDIA-TRACHOMATIS | en |
dc.subject | INTRAEPITHELIAL | en |
dc.subject | NEOPLASIA | en |
dc.subject | CERVICOVAGINAL LAVAGE | en |
dc.subject | GENOTYPE DISTRIBUTION | en |
dc.subject | NONPREGNANT | en |
dc.subject | WOMEN | en |
dc.subject | Virology | en |
dc.title | Applicability of self-obtained urine and vaginal samples for HPV-16,-18,-31 and-45 cervical cancer screening in pregnancy: a pilot cross-sectional study | en |
dc.type | journalArticle | en |